Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada

This article has been Reviewed by the following groups

Read the full article

Discuss this preprint

Start a discussion What are Sciety discussions?

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2021.12.24.21268382: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Ethicsnot detected.
    Sex as a biological variableOmicron cases were matched to Delta cases using up to 2:1 matching on gender (male, female, other), age (0-4, 5-11, 12-18, 19-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80+), vaccination status (0 doses, 1 dose, 2 doses, 3 doses), time since most recent dose (>7 or 14 days to <3 months, 3-6 months, >6 months), region and onset date (±7 days).
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    Delta cases included those detected by WGS, those with amplification of the S-gene, and all cases not identified as Omicron prior to December 3 (date of 5% Omicron prevalence)2.
    WGS
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Our study has some limitations, in particular the short follow-up duration and potential misclassification due to incidental findings from hospital admission screening, and incomplete public health follow-up as incidence increased. Nevertheless, Omicron appears to demonstrate lower disease severity for both vaccinated and unvaccinated individuals. While severity is likely to be reduced, the absolute number of hospitalizations and impact on the healthcare system is likely to be significant due to the large number of Omicron infections.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.